Merit Medical Systems

Merit Medical Systems, Inc. engages in the manufacture and marketing of proprietary disposable medical devices. It operates through the Cardiovascular and Endoscopy segments. The Cardiovascular segment consists of peripheral intervention, cardiac intervention, interventional oncology and spine, and cardiovascular and critical care product groups. The Endoscopy segment integrates non-vascular stent technology with balloon dilators, inflation devices, guide wires, procedure kits, and other devices that are used by gastroenterologists, endoscopists, pulmonologists, and thoracic and general surgeons. The company was founded by Fred P. Lampropoulos, Darla Gill, Kent W. Stanger, and William Padilla in July 1987 and is headquartered in South Jordan, UT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merit Medical Systems reports robust Q4 performance and eyes growth

Merit Medical Systems delivered a strong Q4 performance with revenue growth, increased gross profit, and exceeding net income expectations.
While facing challenges in certain segments and regulatory compliance, the company remains optimistic about growth opportunities and operational improvements.
Strategic pricing initiatives and a focus on achieving financial targets position Merit Medical for continued success and potential expansion through M&A activities.
The company's commitment to discipline, prioritization, and operational excellence underscores its resilience and potential for sustained growth in the future.

Merit Medical Systems posts strong Q1 results, eyes debt reduction

Merit Medical Systems delivered robust financial results in Q1 2023, showcasing growth in revenue, operating income, and net income. The company maintains its financial guidance for 2023, emphasizing a commitment to debt reduction and free cash flow targets. Analyst inquiries highlighted areas for improvement and strategic focus moving forward.

Merit Medical Systems reports robust Q2 earnings amidst strategic acquisitions

Merit Medical Systems delivered strong financial performance in Q2 2023, marked by revenue growth, improved profitability, and strategic acquisitions. While facing challenges in the Endoscopy segment and uncertainties in international markets, the company remains focused on leveraging opportunities in catch-up procedures and strategic M&A for sustainable growth.

Merit Medical Systems excels in Q3, eyes growth opportunities

Merit Medical Systems delivered a strong Q3 performance with notable revenue growth, profit increases, and enhanced net income and EPS.
While facing challenges like margin pressure and regional headwinds, the company remains focused on long-term growth strategies and operational efficiency.
With opportunities for revenue expansion, product advancements, and margin improvements on the horizon, Merit Medical Systems is poised for continued success and shareholder value creation.

Merit Medical Systems excels in Q4 2023, eyes strategic growth

Merit Medical Systems delivered strong financial results in Q4 2023, driven by revenue growth and margin expansion.
The company's strategic initiatives and focus on operational efficiency position it well for future growth and profitability.
Challenges such as SKU rationalization and China revenue decline require careful management and strategic planning.
Opportunities in M&A, pricing power initiatives, R&D investments, and gross margin expansion strategies offer avenues for continued success.

Merit Medical Systems excels in Q1, eyes growth opportunities

Merit Medical Systems delivered strong Q1 results with revenue growth and profitability improvements, driven by operational progress and strategic focus on innovation.
While facing challenges such as pricing pressures in China and debt reduction strategies, the company remains poised for growth through new opportunities and market strategies.
With a solid performance in Q1 and positive Q2 guidance, Merit Medical Systems demonstrates resilience and a strategic approach to navigating industry challenges.
The company's commitment to financial stability, innovation, and shareholder value sets a strong foundation for future growth and market competitiveness.

Merit Medical Systems reports robust Q3 results amidst supply challenges

Merit Medical Systems delivered strong financial results in Q3, driven by revenue growth and margin improvement.
The company's strategic acquisition and focus on innovation position it well for future growth despite supply chain disruptions.
Challenges in supply chain management and analyst inquiries highlight areas for ongoing attention and improvement.
Overall, Merit Medical Systems maintains a positive outlook on its performance and growth trajectory.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merit Medical (MMSI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Merit Medical (MMSI) Expected to Beat Earnings Estimates: Should You Buy?

Merit Medical's (MMSI) latest well-designed tray is expected to simplify the thoracostomy procedure and reduce treatment time, especially in critical situations.

Merit Medical's (MMSI) Latest Launch to Boost Patient Outcome

Intuitive design facilitates procedural efficiency, supports minimally invasive patient care Intuitive design facilitates procedural efficiency, supports minimally invasive patient care

Merit Medical Announces Launch of ReSolve® Thoracostomy Tray

SOUTH JORDAN, Utah, April 13, 2022 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy, announced today that it will release its financial results for the quarter ended March 31, 2022, after the close of the stock market on Wednesday, April 27, 2022.

Merit Medical Systems to Announce First Quarter Results on April 27, 2022

Merit Medical's (MMSI) receipt of FDA clearance for the SCOUT Bx system can streamline treatment for cancer patients.

Merit Medical's (MMSI) SCOUT Bx Delivery System Gets FDA Nod

New technology is designed to allow physicians to place SCOUT® reflector at time of biopsy for breast localization under stereotactic and MRI guidance New technology is designed to allow physicians to place SCOUT® reflector at time of biopsy for breast localization under stereotactic and MRI guidance

Merit Medical Receives FDA Clearance for SCOUT Bx™ Delivery System

Investors continue to be optimistic about Merit Medical (MMSI) owing to its strong product portfolio.

Here's Why You Should Retain Merit Medical (MMSI) Stock For Now

Merit Medical has been posting healthy revenue growth and should see a pickup in oncology and cardiology procedures as hospitals work through their elective procedure backlogs.

Merit Medical's Underperformance Seems Overdone As Elective Procedures Normalize

Receipt of the Breakthrough Device Designation for Merit Medical's (MMSI) Embosphere Microspheres is expected to improve patient outcome.

Merit Medical's (MMSI) Product Included in FDA's Program

SOUTH JORDAN, Utah, March 07, 2022 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), announced today that it has received “breakthrough device designation” from the U.S. Food & Drug Administration (FDA) for Embosphere® Microspheres for the Genicular Artery Embolization (GAE) indication.

Merit Medical Receives FDA “Breakthrough Device Designation” for Embosphere® Microspheres for Use in Genicular Artery Embolization for Symptomatic Knee Osteoarthritis

Merit Medical (MMSI), in the fourth quarter, benefits from revenue growth in both its segments, and from majority of the product categories within its Cardiovascular unit.

Merit Medical's (MMSI) Q4 Earnings, Revenues Top Estimates

Merit Medical Systems' (MMSI) CEO Fred Lampropoulos on Q4 2021 Results - Earnings Call Transcript

Merit Medical (MMSI) delivered earnings and revenue surprises of 42% and 3.17%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Merit Medical (MMSI) Beats Q4 Earnings and Revenue Estimates

*  Constant currency revenue; constant currency revenue, organic; core revenue; non-GAAP EPS; non-GAAP net income; non-GAAP operating income and margin; non-GAAP gross margin; and free cash flow are non-GAAP financial measures. A reconciliation of these financial measures to their most directly comparable GAAP financial measures is included under the heading “Non-GAAP Financial Measures” below.

Merit Medical Reports Results for Fourth Quarter and Year Ended December 31, 2021, Issues FY 2022 Guidance

Merit Medical (MMSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Merit Medical (MMSI) Q4 Earnings Expected to Decline

SOUTH JORDAN, Utah, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy, announced today that it will release its financial results for the fourth quarter and year ended December 31, 2021, and issue FY 2022 guidance after the close of the stock market on Thursday, February 24, 2022.

Merit Medical Systems to Announce Fourth Quarter and Year End 2021 Results on February 24, 2022

SOUTH JORDAN, Utah, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading manufacturer and marketer of proprietary medical devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy, announced today that it has reached an agreement in principle to settle the securities class action lawsuit against Merit and its Chief Executive Officer and Chief Financial Officer currently pending in the United States District Court for the Central District of California. The lawsuit was filed in June 2020 after Merit's stock price declined following disclosures made by Merit with respect to its operating and financial performance during 2019. The settlement was reached following a voluntary mediation process.

Merit Medical Announces Agreement in Principle to Settle Class Action Litigation

Merit Medical (MMSI), in the third quarter, benefits from revenue growth in its Cardiovascular segment, and from the majority of the product categories within its Cardiovascular unit.

Merit Medical's (MMSI) Q3 Earnings, Revenues Top Estimates

Merit Medical Systems, Inc (MMSI) CEO Fred Lampropoulos on Q3 2021 Results - Earnings Call Transcript

Merit Medical (MMSI) delivered earnings and revenue surprises of 18.18% and 2.36%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Merit Medical (MMSI) Surpasses Q3 Earnings and Revenue Estimates

Merit Medical Reports Results For Quarter Ended September 30, 2021

Merit Medical (MMSI) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

SOUTH JORDAN, Utah, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy, announced today that it will release its financial results for the quarter ended September 30, 2021, after the close of the stock market on Thursday, October 28, 2021.

Merit Medical Systems to Announce Third Quarter Results on October 28, 2021

Integer Holdings

Orthofix International

Backed by robust long-term prospects, investors can add three lucrative MedTech stocks, MMSI, ITGR and OFIX, to their watchlist.

3 Promising MedTech Stocks to Snap Up in Second-Half 2021

Prospective, observational study published in CardioVascular and Interventional Radiology 1 reports 100% target lesion primary patency (“TLPP”) rate without reintervention through 30 days, with a 12-month TLPP rate of 84.6% and a 12-month access circuit primary patency (“ACPP”) rate of 65.9%.

News for Merit Medical Systems Stock (MMSI)